19X.F Axsome Therapeutics Inc

Healthcare Biotechnology Frankfurt Exchange
133.30 EUR
Close of Nov 12, 2026
113.05 221.20
Market cap
EUR 7.01B
P/E
-
P/B
70.48x
ROE
-162.8%
Dividend yield
-
Fundamental score
-

Ratios use the latest price and the current fiscal year annualized from 3 quarters up to Sep 2026.

Is 19X.F undervalued?

Graham number

The Graham number of Axsome Therapeutics Inc cannot be estimated reliably (it needs positive earnings and book value).

Graham number = √(22.5 × EPS × book value per share): the most a defensive investor should pay according to Benjamin Graham. An estimate, not a recommendation to buy or sell. How is it calculated?

Axsome Therapeutics Inc fundamental analysis

No fundamental analysis for Axsome Therapeutics Inc yet.

Axsome Therapeutics Inc stock price

Prices on the chart can differ slightly from the closing prices StockSummer uses for its ratios.

About Axsome Therapeutics Inc

Axsome Therapeutics, Inc., a biopharmaceutical company, develops and delivers novel therapies for the management of central nervous system (CNS) disorders in the United States. The company's commercial product portfolio includes Auvelity (dextromethorphan-bupropion), a N-methyl-D-aspartate receptor antagonist, sigma-1 receptor agonist, aminoketone, and CYP2D6 inhibitor indicated for the treatment of major depressive disorder in adults; Sunosi (solriamfetol), a dopamine and n…

Full company profile